Antiretroviral Therapy Recommendations for Adults with Advanced Immunosuppression (CD ≤ 35 cells/µL)

Preferred First‑Line Regimens (Integrase Strand Transfer Inhibitor‑Based)

Regimens to Avoid in Severe Immunosuppression (CD < 200 cells/µL)

Alternative Regimens When Integrase Inhibitors Cannot Be Used

Baseline Laboratory Assessments (Do Not Delay ART Initiation)

Monitoring Schedule After ART Initiation

Adherence Support and Clinical Follow‑Up

HIV Treatment Based on Viral Load and CD4 Count

When to Initiate Treatment

• The American Academy of HIV Medicine recommends that all HIV-infected adults with detectable viremia should start antiretroviral therapy immediately, regardless of CD4 count or viral load level 5, 6, 7
• The decision to start ART is no longer based on CD4 thresholds—treatment is universally recommended for all patients with established HIV infection and detectable plasma virus 5, 6, 8
• Start ART as soon as possible after HIV diagnosis, ideally at the first clinic visit 7
• In acute HIV infection, initiate treatment immediately to reduce viral reservoir seeding 5, 6

Recommended Initial Regimens

• The preferred approach is an integrase strand transfer inhibitor (InSTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs) 5, 6, 7
• Top-tier options include Bictegravir/TAF/emtricitabine, Dolutegravir plus tenofovir/emtricitabine, and Dolutegravir/lamivudine (two-drug regimen) with specific conditions 7, 9
• Alternative InSTI-based regimens include Dolutegravir/abacavir/lamivudine, Raltegravir plus TAF/emtricitabine, and Elvitegravir/cobicistat/TAF/emtricitabine 5, 7, 9

Critical Pre-Treatment Considerations

• Draw labs before the first ART dose, but do not delay treatment while waiting for results, including HIV-1 RNA viral load, CD4 cell count, genotypic resistance testing, and HLA-B*5701 allele testing 9, 10
• Patients with drug resistance mutations require special consideration, including avoiding certain regimens and using alternative anchors like boosted darunavir plus TAF/emtricitabine 5, 9, 11
• Patients with renal impairment should avoid tenofovir disoproxil fumarate (TDF) and prefer tenofovir alafenamide (TAF) for better renal and bone safety profile 5, 9, 11
• Patients with hepatitis B co-infection must include tenofovir (TAF or TDF) plus lamivudine or emtricitabine in their regimen 5, 8
• Pregnant individuals should prefer TAF/emtricitabine plus dolutegravir, with alternative options available 7

Monitoring After Treatment Initiation

• Check HIV RNA every 4-6 weeks after starting or changing ART until undetectable, with a target of HIV RNA <50 copies/mL by 24 weeks 10
• Once suppressed for 1 year, monitor every 3 months, and after 2 years of suppression with stable adherence, can extend to every 6 months 10
• CD4 monitoring frequency depends on baseline count and viral suppression, with less frequent monitoring for those with higher CD4 counts and sustained viral suppression 10
• Pneumocystis pneumonia prophylaxis should be initiated if CD4 <200 cells/μL, and primary MAC prophylaxis is no longer recommended if effective ART is initiated promptly 9, 10